Esophageal cancer is often diagnosed at an advanced stage, with many patients found to have locoregional or metastatic disease at time of diagnosis. Because of this, cure may be unlikely, leading treatment efforts to focus more on symptom palliation and improving patient quality of life. The majority of patients with advanced disease suffer from some degree of dysphagia. Palliative efforts are therefore directed at relieving dysphagia, allowing patients to manage their oropharyngeal secretions, reduce aspiration risk, and maintain caloric intake orally. A variety of endoscopic treatment modalities have been utilized with these objectives in mind, with options determined by the location and size of the tumor, as well as the patient's expected prognosis. In this article, we review the use of endoscopically-placed stents for palliation in patients with advanced esophageal cancer. We discuss the history of stent use in such cases, as well as more recent developments in stent technology. We give an overview of some of the more commonly used stents in practice, discuss the technique of insertion, and survey the short- and long-term outcomes of stent placement.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3168502PMC
http://dx.doi.org/10.5402/2011/719575DOI Listing

Publication Analysis

Top Keywords

esophageal cancer
8
patients advanced
8
esophageal stenting
4
stenting setting
4
setting malignancy
4
malignancy esophageal
4
cancer diagnosed
4
diagnosed advanced
4
advanced stage
4
patients
4

Similar Publications

miR-542-3p/PIK3R1 axis is involved in hsa_circ_0087104-mediated inhibition of esophageal squamous cell carcinoma metastasis.

Am J Cancer Res

December 2024

Department of Breast Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University Hangzhou 310003, Zhejiang, China.

Esophageal squamous cell carcinoma (ESCC), the most predominant subtype of esophageal cancer, is notorious for its high lymph node metastatic potential and poor prognosis. Growing evidence has demonstrated crucial function of circRNAs in human malignancies. However, the knowledge of circRNAs in lymph node metastasis of ESCC is still inadequate.

View Article and Find Full Text PDF

Poor oral health is an independent risk factor for upper-aerodigestive tract cancers, including esophageal squamous cell carcinoma (ESCC); thus, good oral health may reduce the risk of ESCC. We previously reported that high expression of Toll-like receptor (TLR) 6, which recognizes peptidoglycan (PGN) from Gram-positive bacteria correlates with a good prognosis after esophagectomy for ESCC. Most beneficial bacteria in the mouth are Gram-positive.

View Article and Find Full Text PDF

Betel nut chewing, common in several Asian populations, is linked to increased cancer risk, including oral, esophageal, gastric, and hepatocellular carcinoma. Aspirin shows potential as a chemopreventive agent. This study investigates the association between aspirin use and cancer risk among betel nut chewers.

View Article and Find Full Text PDF

Global burden of five major types of gastrointestinal cancer.

Prz Gastroenterol

July 2024

Department of Medicine, Division of Gastroenterology and Hepatology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, US.

Gastrointestinal (GI) cancers cause major global morbidity and mortality, with over 5 million new cases and 3.5 million deaths in 2020. The most prevalent GI malignancies are colorectal, gastric, liver, oesophageal, and pancreatic cancers.

View Article and Find Full Text PDF

Risk Factors Predicting Outcomes in Advanced Upper Gastrointestinal Cancers Treated With Immune Checkpoint Inhibitors.

Gastroenterology Res

December 2024

Division of Medical Oncology, Department of Internal Medicine, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.

Background: Immune checkpoint inhibitors (ICIs) have moved to the frontline in recent years to manage upper gastrointestinal (UGI) tumors, such as esophageal and gastric cancers. This retrospective review sheds light on real-world data on ICI-treated UGI tumors to identify risk factors (clinical and pathological) impacting the outcome other than traditional biomarkers (programmed cell death ligand 1 (PD-L1) or microsatellite instability status).

Methods: Patients with UGI tumors who received at least one dose of ICI for stage IV or recurrent disease between January 1, 2015, and July 31, 2021, at The Ohio State University were included in the study.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!